Business Context and Reporting Period
Company: American Healthcare REIT, Inc. (AHR)
Filing Type: Form 8-K (Current Report)
Date of Report: February 27, 2026
Event: Entry into a Material Definitive Agreement (ATM Equity Offering Sales Agreement).
Key Financial Metrics and Capital Structure
This filing details a capital raising mechanism rather than reporting operational financial results (revenue, profit, or cash flow) for a specific period.
- Proposed Offering Size: Up to $1.75 billion in aggregate gross sales price of Common Stock.
- Previous Program Termination: The prior ATM program (dated August 8, 2025) was terminated with $230,139,575 remaining unsold.
- Compensation to Agents: Commissions will not exceed 2.0% of the gross sales price for shares sold as agents or forward sellers.
- Use of Proceeds: Net proceeds will be contributed to the Operating Partnership for general corporate purposes, including repaying indebtedness, working capital, capital expenditures, and potential future investments.
Material Changes Versus Prior Period
The primary material change is the replacement of the previous at-the-market offering program with a new, larger facility.
- Program Capacity: The new agreement authorizes sales up to $1.75 billion, replacing the prior agreement which had $230.1 million remaining unsold at termination.
- Underwriting Structure: The new agreement involves a syndicate of agents including BofA Securities, Barclays, Citigroup, and others, acting as sales agents or forward sellers.
- Forward Sale Mechanism: The company may enter into forward sale agreements where Forward Purchasers borrow and sell shares to hedge exposure. The company will not receive proceeds from these specific borrowed share sales but may settle obligations physically or via cash/net share settlement.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use the proceeds for general corporate purposes, specifically highlighting debt repayment and capital expenditures. Sales will depend on market conditions, trading price, and capital needs.
Risks and Contingencies:
- Market Dependency: Actual sales are not guaranteed and depend on market conditions and the trading price of Common Stock.
- Dilution: The issuance of shares up to $1.75 billion may result in significant dilution to existing shareholders.
- Forward Price Adjustments: In forward sale agreements, the forward price is subject to daily adjustments based on floating interest rates and reductions for quarterly dividends, which could impact the net proceeds received upon settlement.
- Commission Costs: The 2.0% commission cap reduces the net capital raised from the gross offering amount.
Important Facts for Investor Verification
- Verify the current trading price of AHR common stock to estimate the potential number of shares to be issued under the $1.75 billion cap.
- Review the company's current debt levels to assess the likelihood of proceeds being used for debt repayment versus new investments.
- Monitor future filings for the execution of specific forward sale agreements and the terms of any physical or cash settlements.
- Check the prospectus supplement dated February 27, 2026, for detailed terms regarding the forward price adjustments and dividend impacts.